The Library
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
Tools
Eggington, S., Tappenden, P., Pandor, A., Paisley, S., Saunders, M., Seymour, M., Sutcliffe, P. (Paul) and Chilcott, J. (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. British Journal of Cancer, 95 (9). pp. 1195-1201. doi:10.1038/sj.bjc.6603348 ISSN 0007-0920.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1038/sj.bjc.6603348
Abstract
For many years, the standard treatment for stage III colon cancer has been surgical resection followed by 5-fluorouracil in combination with folinic acid (5-FU/LV). Ongoing clinical trial evidence suggests that capecitabine and oxaliplatin (in combination with 5-FU/LV) may improve disease-free survival and overall survival when compared against 5-FU/LV alone in the adjuvant setting. This study evaluates the cost-effectiveness profiles of these two regimens in comparison to standard chemotherapy, using evidence from two international randomised controlled trials. Survival modelling techniques were employed to extrapolate survival curves from the two trials in order to estimate the long-term benefits of alternative treatment options over the remaining lifetime of patients. The health economic analysis suggests that capecitabine is expected to produce greater health gains at a lower cost than 5-FU/LV. Oxaliplatin in combination with 5-FU/LV is estimated to cost £2970 per additional QALY gained when compared to 5-FU/LV alone. Future research should attempt to elucidate uncertainties concerning the optimal roles of capecitabine and/or oxaliplatin in the adjuvant setting in order to achieve the maximum level of clinical benefit.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
Journal or Publication Title: | British Journal of Cancer | ||||
Publisher: | Nature Publishing Group | ||||
ISSN: | 0007-0920 | ||||
Official Date: | 2006 | ||||
Dates: |
|
||||
Volume: | 95 | ||||
Number: | 9 | ||||
Page Range: | pp. 1195-1201 | ||||
DOI: | 10.1038/sj.bjc.6603348 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |